Dormax 500Mg Inj (Doripenem SOLUTION) 500 MG

Doripenem exerts its antibacterial effect by binding to penicillin‑binding proteins, which blocks the final step of peptidoglycan cross‑linking in bacterial cell walls. This inhibition leads to loss of cell wall integrity and bacterial cell death, and the molecule is resistant to many β‑lactamases.

The specific dose of Dormax 500Mg Inj is determined by the prescribing clinician based on the infection type, severity, patient weight, renal function, and other clinical factors. No fixed regimen is provided here; dosing must follow the prescriber’s order.

Safety data for doripenem in pregnancy and lactation are limited, and the pregnancy category is listed as unknown. It should only be used when the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Dormax 500Mg Inj. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Dormax (doripenem) shares the broad‑spectrum activity of carbapenems such as imipenem and meropenem but has a slightly lower propensity for inducing seizures and offers enhanced stability against certain β‑lactamases. Choice among carbapenems depends on local resistance patterns, patient renal function, and specific safety considerations.

Dormax 500Mg Inj must be stored at 2‑8 °C in a refrigerator, protected from light. The vial should not be frozen or shaken. If the product is removed from refrigeration for a short period, it should be used promptly and returned to the controlled temperature environment as soon as possible.

Dormax is supplied as a sterile injection solution for intravenous infusion. It is typically reconstituted with a compatible diluent and administered over a prescribed period, often 30 minutes to 1 hour, under aseptic conditions by qualified healthcare personnel.

The most serious adverse events associated with Doripenem include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe hypersensitivity reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis, which can be life‑threatening.

Dormax should be avoided in patients with a known hypersensitivity to doripenem, other carbapenems, or any component of the formulation. Caution is also required for individuals with severe renal impairment who have not had dose adjustment, and for those with a history of seizures unless benefits outweigh risks.